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Soft tissue sarcomas
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Background. Retroperitoneal sarcomas are rare presentation for soft-tissue sarcomas. Due to scarcity of these tumors, a pooled
analysis with data from 2 experienced centres in the use of IOeRT was performed. The aim of present analysis is to update the
evolutive experience containing IOeRT in the multimodal approach to retroperitoneal soft-tissue sarcomas.
Patients and methods. From January 1996 to December 2011, 49 patients (p) (39 from UHGM and 9 from UHRYC) with pathologically
conﬁrmed retroperitoneal soft tissue sarcoma were entered into a data registry of IOeRT as a component of multidisciplinary
treatment. Patients’ registry included 29 females and 19 males with a median age of 49 years (range 4–75 years). Thirty p pre-
sentedwith local recurrences of previously treated intra-abdominal sarcomas (64%)while in 18 cases (46%)was anewly diagnosed
disease. Histological subtypes treated were: liposarcoma in 22 p (46%), leiomyosarcoma in 11 p (23%), malignant ﬁbrous histiocy-
toma 3 p (6%), rhabdomyosarcoma 3 p (6%), extraskeletal Ewing’s sarcoma 2 p (4%) and sarcoma not otherwise speciﬁed (NOS),
extraskeletal chondrosarcoma, ﬁbrosarcoma, malignant hemangiopericytoma, malignant mesenchimoma, malignant schwan-
noma and PNET in 1 patient each (15%). All patients underwent a surgical procedure achieving an R0 resection in 27 p (56%), R1
resection in 17 p (35%), R2 resection in 3 p (6%). No information was available from 1 patient (Rx resection). IOeRT was deliv-
ered by using electron-beams (median energy: 9MeV, range 4–18MeV) from non-dedicated linear accelerators. A median dose
of 12.5Gy (range 10–20Gy) was delivered with maximal diameter dimension ranging from 5cm to 24 cm (median 10 cm). Seven
p (15%) had preoperative external beam radiotherapy (EBRT) up to a total median dose of 54Gy (range 45–58Gy), whereas 27 p
(56%) underwent postoperative EBRT to a median dose of 45Gy (range 39.6–54Gy). In 12 p (25%) systemic chemotherapy was
administered.
Results. Response to multidisciplinary treatment was considered as complete in 46 p (96%) while partial in 2 p (2%). Twenty-six
(54%) out of the 46 p achieving a complete response developed locoregional relapse (29%), distant metastases (10%) or both (15%).
With a median follow-up of 35 months (range 9–192 months), 5-year actuarial overall survival (OS) locoregional relapse free
survival (LRRFS) and distant metastases free survival (DMFS) were 52%, 48% and 66% respectively. Toxicity was registered in 47 p.
Acute side-effects were observed in 26 p (54%), including 5 p with fatal toxicity grade 5, whereas late complications were recorded
in 13 p (27%).
Conclusions. IOeRT is a feasible and attractive alternative for the treatment of retroperitoneal soft-tissue sarcomas in the context
of a multidisciplinary approach. Joint analysis of data from expert centres performing similar multimodal treatments is a valid
alternative to achieve robust and reliable data for results interpretation.
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